HUE060364T2 - Vegyületek és konjugátumaik - Google Patents

Vegyületek és konjugátumaik

Info

Publication number
HUE060364T2
HUE060364T2 HUE20713873A HUE20713873A HUE060364T2 HU E060364 T2 HUE060364 T2 HU E060364T2 HU E20713873 A HUE20713873 A HU E20713873A HU E20713873 A HUE20713873 A HU E20713873A HU E060364 T2 HUE060364 T2 HU E060364T2
Authority
HU
Hungary
Prior art keywords
conjugates
compounds
Prior art date
Application number
HUE20713873A
Other languages
English (en)
Hungarian (hu)
Inventor
Philip Howard
Niall Dickinson
Thais Cailleau
Luke Masterson
William Goundry
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69960637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE060364(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HUE060364T2 publication Critical patent/HUE060364T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detail Structures Of Washing Machines And Dryers (AREA)
HUE20713873A 2019-03-29 2020-03-23 Vegyületek és konjugátumaik HUE060364T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826393P 2019-03-29 2019-03-29
US202062964177P 2020-01-22 2020-01-22

Publications (1)

Publication Number Publication Date
HUE060364T2 true HUE060364T2 (hu) 2023-02-28

Family

ID=69960637

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE20713873A HUE060364T2 (hu) 2019-03-29 2020-03-23 Vegyületek és konjugátumaik

Country Status (29)

Country Link
US (3) US20220211863A1 (enExample)
EP (2) EP3946464B1 (enExample)
JP (2) JP7210770B2 (enExample)
KR (3) KR20240104214A (enExample)
CN (4) CN118221763A (enExample)
AU (1) AU2020252034B2 (enExample)
BR (1) BR112021018986A2 (enExample)
CA (1) CA3133757A1 (enExample)
CL (1) CL2021002498A1 (enExample)
CO (1) CO2021014566A2 (enExample)
CR (1) CR20210541A (enExample)
DK (1) DK3946464T3 (enExample)
EC (1) ECSP21078204A (enExample)
ES (1) ES2930295T3 (enExample)
HR (1) HRP20221280T1 (enExample)
HU (1) HUE060364T2 (enExample)
IL (1) IL286291B2 (enExample)
LT (1) LT3946464T (enExample)
MX (1) MX2021011812A (enExample)
PH (1) PH12021552363A1 (enExample)
PL (1) PL3946464T3 (enExample)
PT (1) PT3946464T (enExample)
RS (1) RS63715B1 (enExample)
SG (1) SG11202110524VA (enExample)
SM (1) SMT202200439T1 (enExample)
TW (2) TWI886667B (enExample)
UA (1) UA129129C2 (enExample)
WO (1) WO2020200880A1 (enExample)
ZA (1) ZA202106612B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210034596A (ko) 2018-07-20 2021-03-30 에프. 호프만-라 로슈 아게 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물
US11493668B2 (en) * 2018-09-26 2022-11-08 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
PH12021552363A1 (en) * 2019-03-29 2022-09-05 Medimmune Ltd Compounds and conjugates thereof
CN114302744B (zh) 2019-07-10 2025-08-26 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CA3166732A1 (en) * 2020-01-22 2021-07-29 Medimmune Limited Compounds and conjugates thereof
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
US20240158410A1 (en) * 2021-02-05 2024-05-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN115703712A (zh) 2021-08-17 2023-02-17 江苏迈威康新药研发有限公司 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物
KR20240120744A (ko) * 2021-12-16 2024-08-07 맵웰 (상하이) 바이오사이언스 컴퍼니, 리미티드 캄프토테신 화합물 및 이의 접합체
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
AU2023229884A1 (en) 2022-03-09 2024-10-10 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
KR20240162086A (ko) 2022-03-11 2024-11-14 아스트라제네카 아베 항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법
JP2025510623A (ja) 2022-03-23 2025-04-15 シンアフィックス ビー．ブイ． Ｐｔｋ７を発現する腫瘍を標的化するための抗体コンジュゲート
IL315205A (en) 2022-03-23 2024-10-01 Synaffix Bv Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
EP4496593A1 (en) 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
CN119212731A (zh) 2022-03-23 2024-12-27 新锐生物技术公司 用于靶向表达Trop-2的肿瘤的抗体缀合物
WO2023178452A1 (en) 2022-03-25 2023-09-28 Zymeworks Bc Inc. Antibody-drug conjugates targeting folate receptor alpha and methods of use
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
EP4665399A1 (en) 2023-02-16 2025-12-24 Astrazeneca AB Combination therapies for treatment of cancer with therapeutic binding molecules
TW202506194A (zh) 2023-04-28 2025-02-16 英商梅迪繆思有限公司 用於治療癌症的ｂ７－ｈ４治療性結合分子
TW202508638A (zh) * 2023-05-12 2025-03-01 大陸商百奧賽圖(北京)醫藥科技股份有限公司 連結子化合物及配體－藥物接合物、其製備方法及用途
US20250051463A1 (en) 2023-07-31 2025-02-13 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
WO2025103192A1 (zh) * 2023-11-16 2025-05-22 上海齐鲁制药研究中心有限公司 一种氘代喜树碱化合物及其制备和应用
WO2025167743A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 抗体药物偶联物及其制备方法和用途
WO2025167742A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 抗体药物偶联物及其制备方法和用途
WO2025191470A1 (en) 2024-03-12 2025-09-18 Astrazeneca Ab Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4939255A (en) 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
JP2754022B2 (ja) * 1988-11-18 1998-05-20 第一製薬株式会社 カンプトテシン類縁体
JP3024013B2 (ja) * 1990-08-14 2000-03-21 杏林製薬株式会社 フルオロエチルカンプトテシン誘導体
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
CN1104409C (zh) 1995-02-22 2003-04-02 第一制药株式会社 氨基四氢萘酮衍生物及其制备方法
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
JPH1095802A (ja) * 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd カンプトテシン誘導体
IN189180B (enExample) 1997-07-09 2003-01-04 Chong Kun Dang Corp
AR030207A1 (es) 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
EP1295864B1 (en) 2001-05-08 2008-12-03 Mitsui Chemicals Polyurethanes, Inc. Process for preparation of 1,5-diaminonaphthalenes
MXPA04005185A (es) 2001-11-30 2004-08-11 Chugai Pharmaceutical Co Ltd Compuestos hexaciclicos.
WO2004073601A2 (en) 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
EP1757609B1 (en) 2004-04-09 2013-10-16 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
CN101835803B (zh) 2007-10-19 2016-05-25 健泰科生物技术公司 半胱氨酸改造的抗tenb2抗体和抗体药物偶联物
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
CN102850400A (zh) 2011-06-30 2013-01-02 周文强 喜树碱衍生物及其制备方法、药物组合物与用途
MX364484B (es) 2012-10-11 2019-04-29 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-fármaco.
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
WO2014121033A1 (en) 2013-02-04 2014-08-07 Fl Therapeutics Llc Soluble complexes of drug analogs and albumin
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
HRP20250673T1 (hr) 2013-12-25 2025-08-01 Daiichi Sankyo Company, Limited Postupak za proizvodnju konjugata anti-trop2 antitijelo-lijek
KR102314913B1 (ko) 2014-01-31 2021-10-19 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
KR102186027B1 (ko) 2014-04-10 2020-12-03 다이이치 산쿄 유럽 게엠베하 항her3 항체-약물 콘주게이트
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
EP3134128B1 (en) 2014-10-03 2019-06-05 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
EP3892305A1 (en) 2015-01-30 2021-10-13 Sutro Biopharma, Inc. Hemiasterlin derivatives for conjugation and therapy
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
MA43354A (fr) * 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
SG10201912173RA (en) 2016-10-07 2020-02-27 Daiichi Sankyo Co Ltd Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
KR20190083654A (ko) 2016-11-10 2019-07-12 메디뮨 엘엘씨 Asct2에 특이적인 결합 분자 및 이의 용도
KR20250040100A (ko) 2016-12-12 2025-03-21 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 면역 체크 포인트 저해제의 조합
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
CN117982673A (zh) 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
TW202532106A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
CN109106951A (zh) 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
PH12021552363A1 (en) * 2019-03-29 2022-09-05 Medimmune Ltd Compounds and conjugates thereof

Also Published As

Publication number Publication date
JP7210770B2 (ja) 2023-01-23
JP7680658B2 (ja) 2025-05-21
KR20230023814A (ko) 2023-02-17
HRP20221280T1 (hr) 2022-12-23
CO2021014566A2 (es) 2021-11-19
IL286291A (en) 2021-10-31
CN117263948B (zh) 2024-11-22
CN113631196B (zh) 2024-03-15
TW202423947A (zh) 2024-06-16
CN118221763A (zh) 2024-06-21
EP3946464B1 (en) 2022-08-31
CN118240003A (zh) 2024-06-25
ECSP21078204A (es) 2021-11-30
MX2021011812A (es) 2021-10-22
IL286291B1 (en) 2024-12-01
ES2930295T3 (es) 2022-12-09
US20220211863A1 (en) 2022-07-07
LT3946464T (lt) 2022-11-10
CN117263948A (zh) 2023-12-22
AU2020252034A1 (en) 2021-11-11
TW202104235A (zh) 2021-02-01
TWI826676B (zh) 2023-12-21
TWI886667B (zh) 2025-06-11
CN113631196A (zh) 2021-11-09
US20210322401A1 (en) 2021-10-21
KR20240104214A (ko) 2024-07-04
KR102679892B1 (ko) 2024-07-02
JP2023065346A (ja) 2023-05-12
PL3946464T3 (pl) 2022-12-19
DK3946464T3 (da) 2022-10-31
CA3133757A1 (en) 2020-10-08
RS63715B1 (sr) 2022-11-30
AU2020252034B2 (en) 2024-02-01
PT3946464T (pt) 2022-11-16
US11446292B2 (en) 2022-09-20
US20200306243A1 (en) 2020-10-01
WO2020200880A1 (en) 2020-10-08
KR20210144845A (ko) 2021-11-30
EP4176904A1 (en) 2023-05-10
KR102498681B1 (ko) 2023-02-09
IL286291B2 (en) 2025-04-01
PH12021552363A1 (en) 2022-09-05
BR112021018986A2 (pt) 2022-01-18
UA129129C2 (uk) 2025-01-22
JP2022528851A (ja) 2022-06-16
CR20210541A (es) 2021-12-20
SG11202110524VA (en) 2021-10-28
SMT202200439T1 (it) 2023-01-13
EP3946464A1 (en) 2022-02-09
ZA202106612B (en) 2022-08-31
CL2021002498A1 (es) 2022-06-03

Similar Documents

Publication Publication Date Title
HUE060364T2 (hu) Vegyületek és konjugátumaik
HUE065882T2 (hu) Interleukin-2-polipeptid-konjugátumok és alkalmazásaik
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
IL285178A (en) Compounds and uses thereof
DK4015003T3 (da) Forbedret antistof-oligonukleotid-konjugat
EP3807644A4 (en) ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
DK3794042T5 (da) Anti-muc1-exatecet-antistof-lægemiddelkonjugat
EP3793613C0 (en) IMMUNOCONJUGATES
HUE053619T2 (hu) Anti-CD123 antitestek és konjugátumok és ezek származékai
EP3973221C0 (de) Stop & go-molch
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
IL285118A (en) Compounds and uses thereof
IL283900A (en) Pharmaceutical combinations
EP3967649C0 (en) LIPID NANOPARTICLE
IL284514A (en) Halo-allylamine compounds and use thereof
PL3710485T3 (pl) Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
EP4069242A4 (en) Combinations
IL269321A (en) Drug-polymer conjugate
CA189120S (fr) Pendentif
EP3973348A4 (en) HEAD MOUNT DISPLAYS
EP4074980A4 (en) FAN
EP3965638C0 (en) VAGINAL SPECULUM
DK3908321T3 (da) Farmaceutisk sammensætning
EP3682831C0 (en) CRYOGENIC APPLICATOR